Executives Buy Into Breakups and Chips

CVS Health became the week's loudest corporate story after the Wall Street Journal reported the company plans to split its pharmacy retail business from its insurance and pharmacy-benefit operations. Filed disclosures show insiders at CVS have been net buyers in recent months. The stock carries a market cap of $113bn and short interest of just 1.2% of free float, suggesting short sellers are not positioned against the restructuring.

Corebridge Financial tops the ORTEX insider buying momentum screen for the past month among US names. The life and retirement insurer, spun out of AIG in 2022, has a market cap of $15.5bn. Insiders have leaned into the stock after a 16% gain year to date. Short interest sits at 5.4% of free float, with 6.5 days to cover.

On the chip front, Intel leads the S&P 500 for insider buying momentum over the past month. The stock has surged 63% year to date. With an RSI of 23, it trades at an oversold level even after that run. Analyst consensus implies 57% further upside. Insider purchases filed this period carry more weight than usual given the absence of a declared 10b5-1 plan.

The heaviest insider selling momentum in the S&P 500 belongs to Quanta Services, up 47% year to date. Executives filing sales into a strong rally is a common pattern, though the discretionary nature of any open-market sales would sharpen the signal.

AppLovin also shows heavy insider selling momentum. The stock is down 66% year to date, making executive sales at these levels more noteworthy. Insiders filing to sell into weakness can indicate concern about further pressure ahead.